(Q51349530)

4 April 2018

title

Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. (English)

1 reference

4 April 2018

1 reference

1

1 reference

4 April 2018

Elena Fogari

4

1 reference

4 April 2018

Angela D'Angelo

5

1 reference

4 April 2018

Arrigo F. Cicero

6

1 reference

4 April 2018

Pamela Maffioli

7

1 reference

4 April 2018

Pietro D Ragonesi

2

object named as

Pietro D Ragonesi

1 reference

4 April 2018

author name string

Anna Carbone

3

1 reference

4 April 2018

language of work or name

English

0 references

publication date

3 November 2012

1 reference

4 April 2018

Expert Opinion on Pharmacotherapy

published in

1 reference

4 April 2018

volume

13

1 reference

4 April 2018

issue

18

1 reference

4 April 2018

page(s)

2581-2591

1 reference

4 April 2018

Global estimates of the prevalence of diabetes for 2010 and 2030

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Neuroendocrine and metabolic effects of adipocyte-derived hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

RETRACTED: Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Dipeptidyl peptidase-4 inhibitors: 3 years of experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

The Glycosylation of Hemoglobin: Relevance to Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Determination of total serum insulin (IRI) in insulin-treated diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Use and abuse of HOMA modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Effects of thiazolidinediones and sulfonylureas in patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Novel resistin promoter polymorphisms: association with serum resistin level in Japanese obese individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Human resistin gene polymorphism is associated with visceral obesity and fasting and oral glucose stimulated C-peptide in the Québec Family Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Chemerin is a novel adipokine associated with obesity and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

The role of TNFalpha and TNF receptors in obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734499

10.1517/14656566.2012.734499

21 January 2018

Identifiers

DOI

1 reference

4 April 2018

PubMed ID

23121473

1 reference

4 April 2018